These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22460248)

  • 1. Accuracy assessment of pharmacogenetic algorithms for warfarin dose prediction in Chinese patients.
    Lei X; Guo Y; Sun J; Zhou H; Liu Y; Liang P; Yan Z
    Am J Hematol; 2012 May; 87(5):541-4. PubMed ID: 22460248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.
    Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary O
    Int J Clin Pharm; 2012 Dec; 34(6):837-44. PubMed ID: 22851439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic.
    Shaw PB; Donovan JL; Tran MT; Lemon SC; Burgwinkle P; Gore J
    J Thromb Thrombolysis; 2010 Aug; 30(2):220-5. PubMed ID: 20204461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative performance of pharmacogenetics-based warfarin dosing algorithms derived from Caucasian, Asian, and mixed races in Thai population.
    Chumnumwat S; Yi K; Lucksiri A; Nosoongnoen W; Chindavijak B; Chulavatnatol S; Sarapakdi A; Nathisuwan S
    Cardiovasc Ther; 2018 Apr; 36(2):. PubMed ID: 29243335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
    Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F
    Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation.
    Xu Q; Xu B; Zhang Y; Yang J; Gao L; Zhang Y; Wang H; Lu C; Zhao Y; Yin T
    Thromb Haemost; 2012 Dec; 108(6):1132-40. PubMed ID: 23015069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.
    Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY
    Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of warfarin pharmacogenetic algorithms in clinical practice.
    Marin-Leblanc M; Perreault S; Bahroun I; Lapointe M; Mongrain I; Provost S; Turgeon J; Talajic M; Brugada R; Phillips M; Tardif JC; Dubé MP
    Pharmacogenomics; 2012 Jan; 13(1):21-9. PubMed ID: 22176621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy.
    Horne BD; Lenzini PA; Wadelius M; Jorgensen AL; Kimmel SE; Ridker PM; Eriksson N; Anderson JL; Pirmohamed M; Limdi NA; Pendleton RC; McMillin GA; Burmester JK; Kurnik D; Stein CM; Caldwell MD; Eby CS; Rane A; Lindh JD; Shin JG; Kim HS; Angchaisuksiri P; Glynn RJ; Kronquist KE; Carlquist JF; Grice GR; Barrack RL; Li J; Gage BF
    Thromb Haemost; 2012 Feb; 107(2):232-40. PubMed ID: 22186998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms.
    Cini M; Legnani C; Cosmi B; Guazzaloca G; Valdrè L; Frascaro M; Palareti G
    Eur J Clin Pharmacol; 2012 Aug; 68(8):1167-74. PubMed ID: 22349464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.
    Shalia KK; Doshi SM; Parikh S; Pawar PP; Divekar SS; Varma SP; Mehta R; Doctor T; Shah VK; Saranath D
    J Assoc Physicians India; 2012 Dec; 60():34-8. PubMed ID: 23781667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
    Scott SA; Jaremko M; Lubitz SA; Kornreich R; Halperin JL; Desnick RJ
    Pharmacogenomics; 2009 Aug; 10(8):1243-55. PubMed ID: 19663669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients.
    You JH; Wong RS; Waye MM; Mu Y; Lim CK; Choi KC; Cheng G
    J Thromb Thrombolysis; 2011 Jan; 31(1):113-8. PubMed ID: 20585834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Warfarin dose prediction in children using pharmacometric bridging--comparison with published pharmacogenetic dosing algorithms.
    Hamberg AK; Friberg LE; Hanséus K; Ekman-Joelsson BM; Sunnegårdh J; Jonzon A; Lundell B; Jonsson EN; Wadelius M
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1275-83. PubMed ID: 23307232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.
    Schwartz JB; Kane L; Moore K; Wu AH
    J Am Med Dir Assoc; 2011 Nov; 12(9):633-8. PubMed ID: 21450231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
    Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
    Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of the warfarin dose with clinical and pharmacogenetic data.
    ; Klein TE; Altman RB; Eriksson N; Gage BF; Kimmel SE; Lee MT; Limdi NA; Page D; Roden DM; Wagner MJ; Caldwell MD; Johnson JA
    N Engl J Med; 2009 Feb; 360(8):753-64. PubMed ID: 19228618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacogenetics of the response to warfarin in Chinese.
    Lam MP; Cheung BM
    Br J Clin Pharmacol; 2012 Mar; 73(3):340-7. PubMed ID: 22023024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.
    Liang R; Li L; Li C; Gao Y; Liu W; Hu D; Sun Y
    J Thromb Thrombolysis; 2012 Jul; 34(1):120-5. PubMed ID: 22528326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients.
    Huang SW; Chen HS; Wang XQ; Huang L; Xu DL; Hu XJ; Huang ZH; He Y; Chen KM; Xiang DK; Zou XM; Li Q; Ma LQ; Wang HF; Chen BL; Li L; Jia YK; Xu XM
    Pharmacogenet Genomics; 2009 Mar; 19(3):226-34. PubMed ID: 19177029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.